SynthesisArchives of disease in childhood. Fetal and neonatal edition2005
Palivizumab for preterm infants. Is it worth it?
Synthesis in Archives of disease in childhood. Fetal and neonatal edition, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Respiratory research · 2018Review
- Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.Immunology · 2016Article
- Probiotics to prevent necrotizing enterocolitis: Too cheap and easy?Paediatrics & child health · 2014Article
- Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.International journal of pediatrics · 2014Review
- Viral bronchiolitis for the clinician.Journal of paediatrics and child health · 2011Review
- Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.Clinical microbiology reviews · 2010Review
- Management of bronchiolitis.Paediatrics and child health · 2009Review
- Article
- The future for lung disease in children.Thorax · 2007Article
- Acute bronchiolitis.BMJ (Clinical research ed.) · 2007Review
- Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).Biologics : targets & therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus infection is an important cause of morbidity. Although palivizumab prophylaxis is widely used, it is uncertain whether the cost is justified. A systematic review was therefore performed of the safety, efficacy, and the likely cost effectiveness of prophylaxis for preterm infants in the United Kingdom using a standard search strategy. The only randomised controlled trial identified showed a reduction in hospital admission but no benefit on more serious outcomes. None of the United Kingdom cost studies showed economic benefit for palivizumab prophylaxis. New treatments are rarely cost effective, and, in the absence of a comprehensive economic assessment, continued use for high risk infants may appear justified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.